Common Contracts
557 similar null contracts by Vera Therapeutics, Inc., Absci Corp, Akero Therapeutics, Inc., others
Akero Therapeutics, Inc. 11,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting AgreementAkero Therapeutics, Inc. • March 6th, 2024 • Pharmaceutical preparations • New York
Akero Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,650,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
ABSCI CORPORATION 16,700,000 Shares of Common Stock Underwriting AgreementAbsci Corp • February 28th, 2024 • Services-commercial physical & biological research • New York
Absci Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 16,700,000 shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 2,505,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
KRATOS DEFENSE & SECURITY SOLUTIONS, INC. 16,666,667 Shares of Common Stock Underwriting AgreementKratos Defense & Security Solutions, Inc. • February 27th, 2024 • Guided missiles & space vehicles & parts • New York
Kratos Defense & Security Solutions, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as the representative (the “Representative”), an aggregate of 16,666,667 shares of common stock, $0.001 par value per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 2,500,000 shares of common stock, $0.001 par value per share, of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock, $0.001 par value per share, of the Company including, without limitation, the Shares, are referred to herein as the “Stock”.
Prime Medicine, Inc. 19,200,001 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,200,005 Shares of Common Stock Underwriting AgreementPrime Medicine, Inc. • February 16th, 2024 • Biological products, (no disgnostic substances) • New York
Prime Medicine, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), (i) an aggregate of 19,200,001 shares of common stock, par value $0.00001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and (ii) pre-funded warrants to purchase an aggregate of 3,200,005 shares of Common Stock of the Company, in a form to be mutually agreed by the Company and the Representatives (the “Warrants”) and, at the option of the Underwriters, up to an additional 3,360,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Warrants are herein referred to as the “Underwritten Securities.” The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The Shares and the Warrants are herein referred as the “Securities.” The shares of Common Stock issuable up
KYVERNA THERAPEUTICS, INC. [ ] Shares of Common Stock Underwriting AgreementKyverna Therapeutics, Inc. • February 1st, 2024 • Biological products, (no disgnostic substances) • New York
Kyverna Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ ] shares of common stock, par value $0.00001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [ ] shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
VERA THERAPEUTICS, INC. 8,064,517 Shares of Class A Common Stock Underwriting AgreementVera Therapeutics, Inc. • January 30th, 2024 • Pharmaceutical preparations • New York
Vera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“J.P. Morgan”), Cowen and Company, LLC (“Cowen”) and Evercore Group L.L.C. (“Evercore”) are acting as representatives (the “Representatives”), an aggregate of 8,064,517 shares (the “Underwritten Shares”) of Class A common stock, par value $0.001 per share, of the Company and, at the option of the Underwriters, up to an additional 1,209,677 shares of Class A common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Class A common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
SpringWorks Therapeutics, Inc. 9,482,758 Shares of Common Stock Underwriting AgreementSpringWorks Therapeutics, Inc. • December 6th, 2023 • Biological products, (no disgnostic substances) • New York
SpringWorks Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 9,482,758 shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,422,413 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
SUPER MICRO COMPUTER, INC. 2,100,700 Shares of Common Stock, par value $0.001 per share Underwriting AgreementSuper Micro Computer, Inc. • December 5th, 2023 • Electronic computers • New York
Super Micro Computer, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 2,000,000 shares of common stock, par value $0.001 per share, of the Company, and certain stockholders of the Company named in Schedule 2 hereto (the “Selling Stockholders”) propose to sell to the several Underwriters an aggregate of 100,700 shares of common stock, par value $0.001 per share, of the Company (collectively, the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 315,105 shares of common stock, par value $0.001 per share, of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the
CARGO Therapeutics, Inc. [•] Shares of Common Stock, par value $0.001 per share Underwriting AgreementCARGO Therapeutics, Inc. • November 6th, 2023 • Biological products, (no disgnostic substances) • New York
CARGO Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“JPM”), Jefferies LLC (“Jefferies”) and Cowen and Company, LLC (“TD Cowen”) are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.” In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary
LEXEO THERAPEUTICS, INC. [•] Shares of Common Stock Underwriting AgreementLexeo Therapeutics, Inc. • October 30th, 2023 • Biological products, (no disgnostic substances) • New York
Lexeo Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Nuvalent, Inc. Common Stock Underwriting AgreementNuvalent, Inc. • October 17th, 2023 • Pharmaceutical preparations • New York
Nuvalent, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 5,357,143 shares (the “Underwritten Shares”) of Class A common stock, par value $0.0001 per share (the “Common Stock”), of the Company, and, at the option of the Underwriters, up to an additional 803,571 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. The Company hereby confirms its agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows:
Scholar Rock Holding Corporation 12,408,760 Shares of Common Stock, par value $0.001 per share Underwriting AgreementScholar Rock Holding Corp • October 12th, 2023 • Biological products, (no disgnostic substances) • New York
Scholar Rock Holding Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 12,408,760 shares (the “Underwritten Shares”) of common stock, par value $0.001 per share (“Common Stock”), of the Company and, at the option of the Underwriters, up to an additional 1,861,314 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
Madison Square Garden Entertainment Corp. 7,150,000 Shares of Common Stock Underwriting AgreementMadison Square Garden Entertainment Corp. • September 22nd, 2023 • Services-miscellaneous amusement & recreation • New York
Sphere Entertainment Group, LLC, a Delaware limited liability company (the “Selling Stockholder”), a stockholder of Madison Square Garden Entertainment Corp., a Delaware corporation (the “Company”), proposes to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 7,150,000 shares of Class A common stock, par value $0.01 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,071,188 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
HILLEVAX, INC. 8,000,000 Shares of Common Stock Underwriting AgreementHilleVax, Inc. • September 20th, 2023 • Biological products, (no disgnostic substances) • New York
HilleVax, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 8,000,000 shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,200,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
SQUARESPACE, INC. 5,000,000 Shares of Class A Common Stock Underwriting AgreementSquarespace, Inc. • September 15th, 2023 • Services-prepackaged software • New York
Certain stockholders named in Schedule 2 hereto (the “Selling Stockholders”) of Squarespace, Inc., a Delaware corporation (the “Company”), propose to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 5,000,000 shares of Class A Common Stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 750,000 shares of Class A Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Class A Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. To the extent that there is not more than one Selling Stockholder named in Schedule 2, the term Selling Stockholders shall mean either the singular or plural as the context requires.
CRINETICS PHARMACEUTICALS, INC. 11,441,648 Shares of Common Stock, par value $0.001 per share Underwriting AgreementCrinetics Pharmaceuticals, Inc. • September 13th, 2023 • Pharmaceutical preparations • New York
Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,441,648 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to 1,716,247 additional shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
LEGALZOOM.COM, INC. 14,000,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementLEGALZOOM.COM, Inc. • September 11th, 2023 • Services-computer processing & data preparation • New York
The selling stockholder named in Schedule 2 hereto (the “Selling Stockholder”) of LegalZoom.com, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”), and, at the option of the Underwriters, up to an additional 2,100,000 shares of common stock, par value $0.001 per share, of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Neumora Therapeutics, Inc. [●] Shares of Common Stock, par value $0.0001 per share Underwriting AgreementNeumora Therapeutics, Inc. • September 11th, 2023 • Biological products, (no disgnostic substances) • New York
Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC and BofA Securities, Inc. are acting as representatives (the “Representatives”), an aggregate of [●] shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Underwriting AgreementSunnova Energy International Inc. • August 16th, 2023 • Electric & other services combined • New York
Sunnova Energy International Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 5,100,000 shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) (such 5,100,000 shares of Common Stock being hereinafter referred to as the “Underwritten Shares”). In addition, the Company proposes to issue and sell to the Underwriters, at the option of the Underwriters, up to an additional 765,000 shares of Common Stock (such 765,000 shares of Common Stock being hereinafter referred to as the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
ALTA EQUIPMENT GROUP INC. 2,200,000 shares of common stock, par value $0.0001 per share Underwriting AgreementAlta Equipment Group Inc. • July 25th, 2023 • Wholesale-industrial machinery & equipment • New York
BLACK DIAMOND THERAPEUTICS, INC. 15,000,000 Shares of Common Stock Underwriting AgreementBlack Diamond Therapeutics, Inc. • June 30th, 2023 • Biological products, (no disgnostic substances) • New York
Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 15,000,000 shares of common stock, par value $$0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 2,250,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Savers Value Village, Inc. [ ⚫ ] Shares of common stock Underwriting AgreementSavers Value Village, Inc. • June 20th, 2023 • Retail-miscellaneous retail • New York
Savers Value Village, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC, Jefferies LLC, Goldman Sachs & Co. LLC and UBS Securities LLC are acting as representatives (the “Representatives”), an aggregate of [ ⚫ ] shares of common stock, par value $0.001 per share, of the Company (the “Underwritten Shares”). In addition, certain stockholders of the Company named in Schedule 2 hereto (the “Selling Stockholders”) propose to sell, at the option of the Underwriters, up to an additional [ ⚫ ] shares of common stock of the Company, (the “Option Shares” and, together with the Underwritten Shares, the “Shares”). The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
CAVA Group, Inc. [l] Shares of Common Stock Underwriting AgreementCava Group, Inc. • June 5th, 2023 • Retail-eating places • New York
CAVA Group, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC, Jefferies LLC and Citigroup Global Markets Inc. are acting as representatives (the “Representatives”), an aggregate of [l] shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional [l] shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
GUARDANT HEALTH, INC. 12,500,000 Shares of Common Stock, par value $0.00001 per share Underwriting AgreementGuardant Health, Inc. • May 25th, 2023 • Services-medical laboratories • New York
Guardant Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 12,500,000 shares of common stock, par value $0.00001 per share (“Common Stock”), of the Company (the “Underwritten Shares”). In addition, the Company proposes to issue and sell, at the option of the Underwriters, up to an additional 1,875,000 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
EVgo Inc. 29,411,765 Underwritten Shares of Class A Common Stock Underwriting Agreement May 17, 2023EVgo Inc. • May 22nd, 2023 • Services-automotive repair, services & parking • New York
EVgo Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 29,411,765 shares of Class A common stock, par value $0.0001 per share, of the Company (“Class A Common Stock” and such shares, the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 4,411,764 shares of Class A Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Class A Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
COHERUS BIOSCIENCES, INC. 11,764,706 Shares of Common Stock Underwriting AgreementCoherus BioSciences, Inc. • May 18th, 2023 • Biological products, (no disgnostic substances) • New York
Coherus BioSciences, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 11,764,706 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,764,705 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”
The Duckhorn Portfolio, Inc. 6,000,000 Shares of Common Stock Underwriting AgreementDuckhorn Portfolio, Inc. • April 5th, 2023 • Beverages • New York
The stockholder named in Schedule 2 hereto (the “Selling Stockholder”) of The Duckhorn Portfolio, Inc., a Delaware corporation (the “Company”), proposes to sell, severally and not jointly, to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 6,000,000 shares of common stock, par value $0.01 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 900,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. To the extent there are no additional Underwriters listed in Schedule 1 other than you, the term Representatives as used herein shall mean you, as Underwriter, and the
Biomea Fusion, Inc. 5,000,000 Shares of Common Stock, par value $0.0001 per share Underwriting AgreementBiomea Fusion, Inc. • April 3rd, 2023 • Pharmaceutical preparations • New York
Biomea Fusion, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“JPM”) and Citigroup Global Markets Inc. (“Citi”) are acting as representatives (the “Representatives”), an aggregate of 5,000,000 shares of common stock, par value $0.0001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 750,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Revolution Medicines, Inc. 13,636,364 Shares of Common Stock Underwriting AgreementRevolution Medicines, Inc. • March 7th, 2023 • Biological products, (no disgnostic substances) • New York
Revolution Medicines, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 13,636,364 shares of common stock, par value $0.0001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 2,045,454 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
EngageSmart, Inc. Shares of Common Stock, par value $0.001 per share Underwriting AgreementEngageSmart, Inc. • March 1st, 2023 • Services-prepackaged software • New York
Certain stockholders named in Schedule 2 hereto (the “Selling Stockholders”) of EngageSmart, Inc., a Delaware corporation (the “Company”), propose to sell to the several underwriters listed in Schedule 1 hereto (collectively, the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 8,000,000 shares (the “Underwritten Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company and, at the option of the Underwriters, up to an additional 1,200,000 shares of Common Stock (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.” To the extent that there is not more than one Selling Stockholder named in Schedule 2, the term Selling Stockholders shall mean either the singular or plural as the context requires.
GLOBANT S.A. 1,200,000 Common Shares Underwriting AgreementGlobant S.A. • February 28th, 2023 • Services-computer processing & data preparation • New York
Globant S.A. (the “Company”), a société anonyme organized under the laws of Luxembourg, having its registered office at 37A Avenue J.F. Kennedy, L-1855, Luxembourg, registered with the Luxembourg Trade and Companies Register under number B 173 727, proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”) who will be subscribing therefor, for whom you are acting as representatives (the “Representatives”), 1,200,000 common shares, nominal value U.S.$1.20 per share (the “Common Shares”) of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 180,000 Common Shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The Company hereby confirms its agreement with the several Underwriters concerning the subscription and purchase and issuance and sale of the Shares, as follows:
Treace Medical Concepts, Inc. 4,761,905 Shares of Common Stock, par value $0.001 per share Underwriting AgreementTreace Medical Concepts, Inc. • February 10th, 2023 • Surgical & medical instruments & apparatus • New York
Treace Medical Concepts, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“J.P. Morgan”) and Morgan Stanley & Co. LLC (“Morgan Stanley”) are acting as representatives (the “Representatives”), an aggregate of 4,761,905 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 714,285 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”. In the event that the Company has a single subsidiary or does not have any subsidiaries, then all references herein to “subsidiaries” of the Company shall be deemed to ref
RxSight, Inc. 4,000,000 Shares of Common Stock, par value $0.001 per share Underwriting AgreementRxSight, Inc. • February 8th, 2023 • Ophthalmic goods • New York
RxSight, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 4,000,000 shares of common stock, par value $0.001 per share (the “Common Stock”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 600,000 shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
VERA THERAPEUTICS, INC. 14,285,715 Shares of Class A Common Stock Underwriting AgreementVera Therapeutics, Inc. • February 2nd, 2023 • Pharmaceutical preparations • New York
Vera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC (“J.P. Morgan”), Cowen and Company, LLC (“Cowen”) and Evercore Group L.L.C. (“Evercore”) are acting as representatives (the “Representatives”), an aggregate of 14,285,715 shares (the “Underwritten Shares”) of Class A common stock, par value $0.001 per share, of the Company and, at the option of the Underwriters, up to an additional 2,142,857 shares of Class A common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Class A common stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
Enlight Renewable Energy Ltd. [●] Ordinary Shares, Par Value NIS 0.1 Per Share Underwriting AgreementEnlight Renewable Energy Ltd. • January 31st, 2023 • Electric services • New York
Enlight Renewable Energy Ltd., a company organized under the laws of the State of Israel (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [●] ordinary shares, par value NIS 0.1 per share (“Ordinary Shares”), of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] Ordinary Shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”.
